Cost Effectiveness of Sevelamer vs Calcium Carbonate in Singaporean Patients with CKD-ND

Countries:

Start Date:

End Date:

  • Ongoing

Cost Effectiveness of Sevelamer vs Calcium Carbonate in Singaporean Patients with CKD-ND

Hyperphosphatemia is a universal problem with chronic kidney disease and is an independent risk factor for increased morbidity and mortality. Phosphate binders can lower the level of phosphate in the blood but lead to their own set of complications with prolonged use. This study will compare the cost-effectiveness of an older calcium based binder with Sevelamer, a new non-calcium based binder, using a Markov model of the Singapore chronic kidney disease population.